The Venture Codex

Participated · Series D · Aug 2024

Moximed's core product is the MISHA Knee System, the first implantable shock absorber designed to reduce about 30% of peak force on the knee with each walking step to relieve pain and preserve function in patients with medial knee osteoarthritis. The implant is placed during an outpatient procedure and has been shown to alleviate pain, improve function, and in some patients delay the need for total knee replacement. The company emphasizes a decade-plus of clinical research and development behind the technology and positions MISHA for patients with mild-to-moderate OA who seek joint-preserving options. Moximed intends to use recent financing proceeds to accelerate U.S. commercialization, expand commercial infrastructure, and broaden patient and surgeon access. The company highlights growing market opportunity given osteoarthritis prevalence in the U.S. and the product's clinical value proposition. Moximed is based in Fremont, California. Moximed, based in Fremont, California, commercializes the Misha knee system — described as the world’s first implantable shock absorber for the knee. The Misha device is designed for implantation during an outpatient procedure to alleviate pain, improve function, enable early weight bearing, and potentially delay total knee replacement for patients with mild-to-moderate osteoarthritis. The company says the system can preserve the native knee and address a treatment gap between conservative care and joint replacement. Moximed will use proceeds from the financing to pursue regulatory approvals and to establish commercial infrastructure for Misha. Results from the company’s pivotal study are slated for presentation on Sept. 22, 2020 at the Orthopedic Summit (OSET) in Boston. The article reports a $40M financing and additional debt financing support from Runway Growth Capital. Moximed develops unicompartmental shock-absorbing implants (KineSpring and Atlas systems) that absorb excess joint load without bone cutting or bone removal. The company reports treatment durability established to nearly nine years on initial patients, and the Atlas System is CE-marked in Europe. Moximed has fully enrolled its FDA pivotal clinical study of the KineSpring System and is currently enrolling a US IDE study of the Atlas System. The Atlas System is designed to provide approximately 30 lbs of unloading, is placed subcutaneously, and aims to preserve future treatment options. Moximed intends to use recent financing to complete FDA approval and support early US commercialization amid strong patient and surgeon interest. The company is backed by venture investors including NEA, Morgenthaler Ventures, Gilde Healthcare, GBS Venture Partners, Vertex Healthcare, Advent Life Sciences, and Future Fund. Moximed focuses on minimally invasive, joint‑preserving solutions for patients with knee osteoarthritis. Its core product is the KineSpring System, a subcutaneous joint‑unloading implant intended for pre‑arthroplasty patients who want to remain active. The KineSpring System is CE marked, available in major European markets, investigational in the U.S., and has been implanted in over 1,000 cases worldwide. The company announced a financing to support efforts to obtain FDA approval for KineSpring and to grow commercial sales in Europe. Moximed is backed by venture investors including Vertex Venture Holdings, New Enterprise Associates, Gilde Healthcare Partners, Morgenthaler Ventures, and GBS Venture Partners. Management cites clinical evidence from its GOAL Study and strong patient interest in joint‑preserving treatments.